Dr. Cedarbaum joined Biogen Idec in April 2014, where he is currently Vice President, Movement and Neuromuscular Disorders Clinical Development. Prior to joining Biogen, Dr. Cedarbaum was Vice President, Global Clinical Development for Neuroscience at Bristol-Myers Squibb, where he was responsible for late-stage programs in neurology and psychiatry. He has also held senior clinical development positions at Cytokinetics, Elan and Regeneron.
Dr. Cedarbaum obtained his medical degree from Yale Medical School. He trained in Internal Medicine at the University of Chicago and did his Neurology residency at New York Hospital-Cornell Medical Center. After residency, Dr. Cedarbaum led the Parkinson and Movement Disorders program there until he joined the pharmaceutical industry. Dr. Cedarbaum is a Fellow of both the American Academy of Neurology and the American Neurological Association. He serves as the Secretary of the Board of Directors of the American Society for Experimental Neurotherapeutics (ASENT), has been a member of the NINDS Parkinson’s Disease Biomarkers Identification Network (PDBIN) Committee and the fNIH Neuroscience Biomarkers Consortium Steering Committee, and was the 2014-15 chair of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board.
